日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study

基孔肯雅热的全球、区域和国家负担:感染力分布图和空间建模研究

Kang, Hyolim; Lim, Ahyoung; Auzenbergs, Megan; Clark, Andrew; Colón-González, Felipe J; Salje, Henrik; Clapham, Hannah; Carrera, Jean Paul; Kim, Jong-Hoon; Malarski, Maya; López-Vergès, Sandra; Cucunubá, Zulma M; Cerqueira-Silva, Thiago; Edmunds, William John; Sahastrabuddhe, Sushant; Brady, Oliver J; Abbas, Kaja

The long-term impact of vaccine clinical research on national stakeholders involved: Experience from a low-income Country

疫苗临床研究对相关国家利益攸关方的长期影响:来自低收入国家的经验

Haque Pial, Rejwana; Rai, Ganesh Kumar; Shrestha, Rajeev; Das, Santa Kumar; Chapagain, Ram Hari; Chaudhary, Shipra; Tamrakar, Dipesh; Kanodia, Piush; Thapa, Pragya; Vemula, Sridhar; Gupta, Birendra Prasad; Hill, Alexandra; Kimathi, Derick; Baiden, Rita; Kim, Hee Soo; Excler, Jean-Louis; Wartel, T Anh; Sahastrabuddhe, Sushant; Saluja, Tarun

Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model.

灭活病毒疫苗 BBV87 在非人灵长类动物模型中可抵抗基孔肯雅病毒攻击

Kempster Sarah L, Ferguson Deborah, Ham Claire, Hall Joanna, Jenkins Adrian, Giles Elaine, Priestnall Simon L, Suarez-Bonnet Alejandro, Roques Pierre, Le Grand Roger, Kandaswamy Sumathy, Sahastrabuddhe Sushant, Hernandez Libia Milena, Chuasuwan Sunee, Ahn Hyeon Seon, Kim Deok Ryun, Wartel Anh, Zellweger Raphaël M, Berry Neil, Almond Neil

Age-specific chikungunya outbreak response immunisation strategies in Brazil: a modelling study

巴西针对不同年龄段的基孔肯雅疫情应对免疫策略:一项建模研究

Kang, Hyolim; Lim, Ahyoung; Clark, Andrew; Colón González, Felipe J; Clapham, Hannah Eleanor; Carrera, Jean-Paul; Kim, Jong-Hoon; Auzenbergs, Megan; Lakshminarayanan, Preethi; López-Vergès, Sandra; Sim, So Yoon; Han, Su Myat; Cerqueira-Silva, Thiago; Endy, Timothy; Cucunubá, Zulma M; Edmunds, W John; Sahastrabuddhe, Sushant; Brady, Oliver J; Abbas, Kaja

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

伤寒结合疫苗(Vi-DT)的安全性和免疫原性:一项观察者盲法、活性对照、随机、非劣效性、III期临床试验在健康志愿者中的研究结果

Tamrakar, Dipesh; Poudel, Pranodan; Thapa, Pragya; Singh, Srijana; Khadgi, Amit; Thapa, Sameera; Tamrakar, Rajendra; Shrestha, Anmol; Madhup, Surendra; Rai, Ganesh Kumar; Gupta, Birendra Prasad; Saluja, Tarun; Sahastrabuddhe, Sushant; Shrestha, Rajeev

Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis

在基孔肯雅疫情高风险国家引入基孔肯雅疫苗的规划考量和证据缺口:利益相关者分析

Auzenbergs, Megan; Maure, Clara; Kang, Hyolim; Clark, Andrew; Brady, Oliver; Sahastrabuddhe, Sushant; Abbas, Kaja

Biases in COVID-19 vaccine effectiveness studies using cohort design

采用队列设计进行新冠疫苗有效性研究的偏倚

Agampodi, Suneth; Tadesse, Birkneh Tilahun; Sahastrabuddhe, Sushant; Excler, Jean-Louis; Kim, Jerome Han

A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity

一项针对健康印尼青少年和成人的Vi-DT伤寒结合疫苗的II期临床试验:为期一个月的安全性和免疫原性评估

Koesnoe, Sukamto; Medise, Bernie Endyarni; Rengganis, Iris; Hadinegoro, Sri Rezeki; Puspita, Mita; Sari, Rini Mulia; Yang, Jae Seung; Sahastrabuddhe, Sushant; Soedjatmiko; Gunardi, Hartono; Sekartini, Rini; Wirahmadi, Angga; Kekalih, Aria; Mukhi, Sreshta; Satari, Hindra Irawan; Bachtiar, Novilia Sjafri

Vaccine value profile for Chikungunya

基孔肯雅疫苗的价值概况

Flandes, Ximena; Hansen, Clairissa A; Palani, Sunil; Abbas, Kaja; Bennett, Cate; Caro, William Perea; Hutubessy, Raymond; Khazhidinov, Kanat; Lambach, Philipp; Maure, Clara; Marshall, Caroline; Rojas, Diana P; Rosewell, Alexander; Sahastrabuddhe, Sushant; Tufet, Marta; Wilder-Smith, Annelies; Beasley, David W C; Bourne, Nigel; Barrett, Alan D T

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

SARS-CoV-2重组蛋白纳米颗粒疫苗GBP510佐剂AS03的免疫原性和安全性:一项随机、活性对照、观察者盲法3期临床试验的中期结果

Song, Joon Young; Choi, Won Suk; Heo, Jung Yeon; Kim, Eun Jin; Lee, Jin Soo; Jung, Dong Sik; Kim, Shin-Woo; Park, Kyung-Hwa; Eom, Joong Sik; Jeong, Su Jin; Lee, Jacob; Kwon, Ki Tae; Choi, Hee Jung; Sohn, Jang Wook; Kim, Young Keun; Yoo, Byung Wook; Jang, In-Jin; Capeding, Maria Z; Roman, François; Breuer, Thomas; Wysocki, Piotr; Carter, Lauren; Sahastrabuddhe, Sushant; Song, Manki; D'Cor, Naveena; Kim, Hun; Ryu, Ji Hwa; Lee, Su Jeen; Park, Yong Wook; Cheong, Hee Jin